In brief: ChemGenex Pharmaceuticals, Novogen, Peptech
Monday, 27 June, 2005
ChemGenex Pharmaceuticals (ASX:CXS) has received approval to list on the NASDAQ SmallCap Market under the ticker CXSP. Trading in the company's American Depositary Receipts (ADR) will be possible from June 28. Each ADR will represent 15 ordinary shares on the ASX.
Novogen (ASX:NRT, NASDAQ:NVGN) has been granted three Australian health supplement patents covering tablets or capsules containing any two of the four main isoflavones: biochanin, formononetin, diadzein and genistein. The patents directly benefit the company's health products Promensil, a natural menopause supplement, and Trinovin, a supplement for prostate health in men, and are in place till 2013.
Peptech's (ASX:PTD) joint venture partner Biosceptre International has been granted an Australian patent related to the diagnostic use of antibodies binding a cancer cell marker in addition to equivalent patents already granted in South Africa, New Zealand and Singapore.
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...
